Associations between HLA and antibodies to collagen in rheumatoid arthritis

M J Rowley, B Tait, T Doran, P Emery, I R Mackay

Abstract

Associations between HLA types and serum antibodies to native and denatured type II collagen were sought in 105 patients with rheumatoid arthritis (RA). Antibodies were measured using a solid phase radioimmunoassay. There were no significant associations between any HLA antigens (A, B, or DR) and a high antibody titre to native collagen. There were significant associations, however, between HLA antigens and high antibody titres to denatured collagen. Although DR4 did not show an association, the phenotype A2*DR4* did; this was not related to A2 as A2*DR- was not associated with a high antibody titre. No single B locus antigen showed an association, but several B locus antigens, B12, B15, and B40, were included in phenotypes with A2 and DR4 which were associated with a high antibody titre to denatured collagen. These HLA associations with anticollagen type II are best explained by a gene other than DR4 (but in linkage with it) which may regulate the antibody response to denatured collagen. If so, this would represent an HLA gene in addition to DR4 that is active in RA.

Rheumatoid arthritis (RA) is a disease with strong immunogenetic associations. Although the primary HLA association found in RA has been with DR4, the distribution of other class I and class II HLA alleles is changed, and certain extended haplotypes ('supratypes') of DR4 occur more commonly than in a healthy population. Moreover, clinical studies have shown associations between HLA alleles and particular patterns of disease. In the study by Jaraquemada et al the prevalence of A2, Cw3, Bw62, Dw4, and DR4 was greater in patients with extra-articular disease, including digital or cutaneous vasculitis, fibrosing alveolitis, and neuropathy, and the prevalence of DR4, Dw4, and A2 was higher in patients with subcutaneous nodules. Sweatman et al have also shown an increased prevalence of A2 and A28 in patients with obliterative bronchiolitis, with or without RA.

Since the early claim that a response to type II collagen might contribute to the pathogenesis of RA, an experimental arthritis has been induced by immunising rodents with type II collagen. In mice susceptibility to arthritis induced by collagen is restricted to those strains with major histocompatibility complex (MHC) haplotypes bearing H-2q, and such strains as those which produce high antibody titres to type II collagen after immunisation. In man autoantibodies to collagen occur commonly in both the serum and synovial fluid of patients with RA. The disease specificity of this association has been contested, but with our use of a rigorous upper limit of normal we have not been able to support the claims that there are associations with other articular or inflammatory diseases including leprosy, or with other autoimmune connective tissue diseases in the absence of arthritis. We have noted, however, that some 15% of patients with systemic lupus erythematosus (SLE) who have polyarthritis also have antibodies to collagen (unpublished data). Accordingly, we see the association between RA and collagen antibodies as disease specific, although the importance of these antibodies has not yet been clarified.

We previously studied 40 HLA typed patients with severe RA, many of whom had vasculitis, and showed that antibody titres to denatured collagen were significantly higher in the serum of those who were DR4 positive than in those who were DR4 negative; antibody titres were also non-significantly associated with those HLA haplotypes which are more prevalent in RA.

This study was designed to achieve the following: (a) extend our previous work on the association between antibodies to collagen and HLA types; (b) include patients with less severe disease; (c) examine associations between collagen antibodies and particular combinations of HLA types which are likely to be components of extended haplotypes (supratypes), and which have been associated with clinical subsets of disease.

Patients and methods

One hundred and five patients with confirmed RA, diagnosed according to the criteria of the American Rheumatism Association and for whom HLA types and serum samples were available, were included in this study: Sixty seven (64%) were DR4 positive and 38 (36%) were DR4 negative; 37 had been tested for antibodies to collagen in the previous study using bovine collagen, but were retested using human collagen. For comparison, titres of antibody to collagen were measured in 50 healthy subjects.

ANTIBODIES TO COLLAGEN

Antibodies to native and denatured type II human collagen were measured in sera using the solid phase radioimmunoassay described previously. Microtitre plates were coated with native collagen or with collagen denatured at

The Reid Memorial Laboratory, Clinical Research Unit of the Walter and Eliza Hall Institute of Medical Research, and the Royal Melbourne Hospital, Melbourne, Australia

M J Rowley
P Emery
I R Mackay

Tissue Typing Laboratories of the Royal Melbourne Hospital
B Tait

Tissue Typing Laboratory, Red Cross Blood Transfusion Service, Sydney
T Doran

Correspondence to: Dr M Rowley, Centre for Molecular Biology and Medicine, Monash University, Clayton, Victoria 3168, Australia.

Accepted for publication 5 September 1989

578


SCIENTIFIC PAPERS
Associations between HLA and antibodies to collagen in RA

50°C, at a concentration of 30 μg/ml collagen. Protein A labelled with 125I was used to detect IgG antibodies bound to the collagen. Serum samples were tested in duplicate, at a dilution of 1/100. Each serum sample was tested in the presence and absence of collagen, and the background binding in the absence of antigen was subtracted from the total counts bound for each serum tested. Serum samples from patients with RA and the comparison groups were tested together.

HLA TYPING
Typing for HLA-A, B, and DR was done by standard microlymphocytotoxicity procedures.20 21 DRw53 was estimated by its association with DR4, DR7, and DR9.

HLA ASSOCIATIONS
Three groups of HLA associations were assessed:

(i) Phenotypes which are more prevalent in RA, and which, from the findings of our previous study,13 may be associated with high antibody titres. These included DR4 and the haplotypes A2; B12; DR4; A2; B15; DR4 and A2; B40; DR42 3 and also DRw53 (MT3).22-24

(ii) Phenotypes which occur less often in RA. These include DR2 and A3; B7; DR2,4 6 25 26 which were previously shown to be associated with a non-significant decrease in antibody to denatured collagen.15

(iii) DR3 and the haplotypes A1; B8; DR3 which have been associated with certain autoimmune diseases27-29 and with high antibody titres to native collagen30 31 but not denatured collagen.15

Antibody was measured as counts per minute (cpm) of radioactivity bound in the radioimmunoassay at a 1/100 dilution to serum. For convenience the cpm for each assay was taken to specify the titre of anticallogen antibody, and results were expressed as mean cpm (SD). As antibody titres within the group with RA were not normally distributed, however, statistical analysis was carried out by the two tailed non-parametric Mann-Whitney U test. Differences were regarded as non-significant if the probability that they arose by chance was greater than 0.05. As there was an a priori reason for the analyses, no correction was applied for multiple comparisons.

Results
The mean antibody titre (1 SD) to native collagen in the 50 healthy controls was 426 (258) cpm and the mean antibody titre in the patients with RA was 1110 (1820) (p<0.001). No significant associations between any HLA haplotypes and a high antibody titre to native collagen were evident (data not shown).

The mean antibody titre to denatured collagen for the 50 healthy controls was 1860 (874) cpm and that for the patients with RA was 4200 (4520) cpm (p<0.001).

Collagen Antibodies in DR4 and DR4 Associated Haplotypes
Associations between HLA and antibody titres to denatured collagen are shown in the table and figure. The mean titre of 4520 (4960) cpm in the 67 patients who were DR4 positive was not significantly higher than the mean of 3630 (3600) cpm in the 38 patients who were DR4 negative. To look at possible haplotypes associated with DR4, combinations of A, B, and DR alleles were examined and patients who were presumed to possess the three most common haplotypes, A2;B12;DR4, A2;B15;DR4, and A2;B40;DR4 were compared with those who did not possess all three. The mean antibody titre of 5820 (5420) was higher in the 23 patients with these putative haplotypes than the mean of

<table>
<thead>
<tr>
<th>Phenotype</th>
<th>Positive</th>
<th>Negative</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>DR4</td>
<td>4520 (4960)</td>
<td>3630 (3600)</td>
<td>0.053</td>
</tr>
<tr>
<td>A2;B12;DR4</td>
<td>(n=67)</td>
<td>(n=38)</td>
<td>0.053</td>
</tr>
<tr>
<td>A2;B15;DR4</td>
<td>(n=23)</td>
<td>(n=82)</td>
<td>NS</td>
</tr>
<tr>
<td>A2;B40;DR4</td>
<td>(n=43)</td>
<td>(n=62)</td>
<td>0.026</td>
</tr>
<tr>
<td>DR4 positive only:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A2</td>
<td>5530 (5610)</td>
<td>2730 (2800)</td>
<td>0.013</td>
</tr>
<tr>
<td>A2</td>
<td>(n=43)</td>
<td>(n=24)</td>
<td>0.013</td>
</tr>
<tr>
<td>DR4 negative only:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A2</td>
<td>3800 (4060)</td>
<td>3170 (1900)</td>
<td>0.047</td>
</tr>
<tr>
<td>A2</td>
<td>(n=28)</td>
<td>(n=10)</td>
<td>0.047</td>
</tr>
<tr>
<td>DRw53</td>
<td>4480 (4740)</td>
<td>3520 (4030)</td>
<td>0.027</td>
</tr>
<tr>
<td>DR2</td>
<td>3730 (3970)</td>
<td>4330 (4670)</td>
<td>0.032</td>
</tr>
<tr>
<td>A3;B7;DR2</td>
<td>(n=76)</td>
<td>(n=27)</td>
<td>0.032</td>
</tr>
<tr>
<td>A3;B7;DR2</td>
<td>(n=43)</td>
<td>(n=62)</td>
<td>0.026</td>
</tr>
<tr>
<td>A1;B8;DR3</td>
<td>3480 (3480)</td>
<td>4360 (4730)</td>
<td>0.064</td>
</tr>
<tr>
<td>A1;B8;DR3</td>
<td>(n=19)</td>
<td>(n=86)</td>
<td>0.064</td>
</tr>
</tbody>
</table>

Antibody titres to denatured collagen, measured as counts of radioactivity bound in the radioimmunoassay, in patients with rheumatoid arthritis, grouped according to HLA phenotype. Horizontal line represents upper limit of normal (mean ± 3 SD of the control group). ● = DR4 positive; ○ = DR4 negative.
3750 (4160) in the remaining 82 patients, but the difference was non-significant (p=0.053). When A2 and DR4 were considered together, however, the mean of 5530 (5610) in 43 patients who were A2 and DR4 positive was significantly higher (p=0.026) than the mean of 3280 (3330) in the 62 patients who lacked A2 and DR4. Moreover, the mean antibody titre in the 23 patients with the putative haplotypes did not differ from the mean of 5190 (5950) in the 20 patients who were A2 and DR4 positive but who were not positive for B12, B15, or B40; no single haplotype would explain the high titres of antibodies in these 20 patients, although B7 or B8, which may occur in haplotypes of DR4, were present in several patients.

To determine whether A2 alone was implicated an association between A2 and a high titre of antibodies was sought separately in patients who were DR4 positive and DR4 negative. For those who were DR4 positive the mean antibody titre of 5530 (5610) in the 43 patients who were A2 positive was significantly higher (p=0.013) than that of 2730 (2800) in the 24 who were A2 negative. For those who were DR4 negative, the mean antibody titre of 3800 (4060) was not significantly higher in the 28 patients who were A2 positive than that of 3170 (1900) in the 10 who were A2 negative. Thus high antibody titres were related to the combination of A2 and DR4 rather than to either alone.

No other significant associations were obtained, although mean titres of antibodies to denatured collagen tended to reflect the known effects of HLA on susceptibility to RA. Thus those patients who were DRw53 positive had higher titres of antibody and those patients who were DR2 or A3; B7; DR2 positive had lower titres.

Discussion

The association between RA and HLA-DR4 is well established and may reflect the presence of a disease susceptibility gene associated with, or closely linked to, DR4.2 Goronyz et al. have used T cell clones to identify Dw14 associated T cell epitopes in all patients with RA tested,32 whether DR4 positive or negative, and suggest that there may be a specific polymorphism(s) within MHC class II molecules that can lead to recognition of an unknown antigen by T lymphocytes. Several genetic studies in RA have suggested that more than one gene is involved in pathogenesis,33–35 and clinical subsets of the disease may be associated with different combinations of HLA antigens.36

One antigen which may be inappropriately recognised in RA might be type II collagen. Both cellular and humoral immunity to collagen have been shown in RA, but HLA associations with the response to collagen have not been clearly shown. Increased cellular38 and humoral responses to collagen have been linked to DR4, but other studies, albeit smaller, have failed to confirm these results.30 40–42 Antibodies to native type II collagen, which are increased in the serum in only about 10% of patients with RA, have been linked with HLA-DR3 and DR7,30 31 but this was not observed in our study.

We have reported the effect of selected HLA types, which have hitherto been linked either positively or negatively with susceptibility to RA, on titres of antibodies to human denatured type II collagen. The specificities examined included DR4, A2+DR4, and the putative haplotypes of DR4, A2;B12;DR4, A2;B15;DR4, and A2;B40;DR4, DRw53, DR2, and A3;B7;DR2, and DR3 and A1;B8;DR3. In each case mean antibody titres to denatured collagen were significantly lower among HLA haplotypes tended to reflect the known effects of HLA on susceptibility to RA. Thus those patients who were DR4 and DRw53 positive had higher titres, and those patients who were DR2 or A3;B7;DR2 positive had lower titres, though no single class I or class II allele was itself significantly associated with high titres of antibodies. Interestingly, A2 and DR4 together were the best markers for high antibody titres to denatured collagen, perhaps reflecting the effect of an unknown gene which occurs in extended haplotypes of DR4; in this study we were unable to identify such haplotypes by their A, B, and DR antigens. Perhaps the antibodies to type II collagen in RA, however, are best explained by a gene other than DR4, but in linkage with it, which may regulate the antibody response to denatured collagen. If so, this would represent an HLA gene other than DR4 that is activated in rheumatoid arthritis.

We thank the members of the department of rheumatology of the Royal Melbourne Hospital for their cooperation and access to patients. Dr. Rowley was supported by a National Research Fellowship. Drs. Mackay and Emery were supported by a grant from the National Health and Medical Research Council of Australia.

14 Rowley M J, Williamson D J, Mackay I R. Evidence for local synthesis of antibodies to denatured collagen in the
Associations between HLA and antibodies to collagen in RA


Associations between HLA and antibodies to collagen in rheumatoid arthritis.

M J Rowley, B Tait, T Doran, P Emery and I R Mackay

doi: 10.1136/ard.49.8.578

Updated information and services can be found at:
http://ard.bmj.com/content/49/8/578

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/